Mirtazapine for obsessive-compulsive disorder: An open trial followed by double-blind discontinuation

Journal of Clinical Psychiatry

Volumn 66, Issue 4, 2005, Pages 515-520

  Koran, Lorrin M ^a,b   Gamel, Nona N ^a   Choung, Helen W ^a   Smith, Emily H ^a   Aboujaoude, Elias N ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; PLACEBO; RISPERIDONE; SERTRALINE; TOPIRAMATE; VENLAFAXINE; ZONISAMIDE;

ADULT; ANORGASMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERSOMNIA; MALE; MOOD DISORDER; NIGHTMARE; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

EID: 17844365291     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0415     Document Type: Article

References (46)

1. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5:181-191
2. Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies. J Clin Psychiatry 1994;55(suppl 3):11-17
3. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-738
4. McDougle CJ, Goodman WK, Leckman JF, et al. The psychopharmacology of obsessive compulsive disorder: implications for treatment and pathogenesis. Psychiatr Clin North Am 1993;15:749-766
5. Rasmussen SA, Eisen JL, Pato MT. Current issues in the pharmacologic management of obsessive compulsive disorder. J Clin Psychiatry 1993; 54(suppl 6):4-9
6. Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 1995; 166:424-443
7. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60:101-106
8. Ackerman DL, Greenland S, Bystritsky A. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1998;18:185-192
9. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am 2000;23:509-518
10. Barr LC, Goodman WK, Price LH, et al. The serotonin hypothesis of obsessive-compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry 1992(suppl 4):17-28
11. Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 1998;59:306-312
12. deBoer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996:57(suppl 4):19-25
13. Koran LM, Quirk T, Lorberbaum JP, et al. Mirtazapine treatment of obsessive-compulsive disorder [letter]. J Clin Psychopharmacol 2001;21:537-539
14. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
15. Pato MT, Zohar-Kadouch R, Zohar J, et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988;145:1521-1525
16. Pato MT, Chakravory S. Discontinuation and long-term treatment of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Practical Management. 3rd ed. St Louis, Mo: Mosby; 1998:625-646
17. Lecrubier Y, Sheehan D, Weiller E, et al. The Mini-International Neuropsychiatric Interview (MINI): a short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997;12: 224-231
18. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, et al. Reliability and validity of the Mini-International Neuropsychiatric Interview (MINI): according to the SCID-P. Eur Psychiatry 1997;12:232-241
19. March JS, Frances A, Carpenter D, et al, eds. The Expert Consensus Guideline Series: Treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry 1997;58(suppl 4):3-72
20. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:75-86
21. Koran LM. Obsessive-Compulsive and Related Disorders in Adults: A Comprehensive Clinical Guide. Cambridge, England: Cambridge University Press; 1999:53-80
22. Hollander E, Friedberg J, Wasserman S, et al. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2003;64: 546-550
23. Goodman WK, Price H, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
24. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
26. Jenike MA, Buttolph L, Baer L, et al. Open trial of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1989;146:909-911
27. Liebowitz MR, Hollander E, Schneier F, et al. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. J Clin Psychopharmacol 1989;9:423-427
28. Albert U, Aguglia E, Maina G, et al. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002;63:1004-1009
29. Rauch SL, O'Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases. J Clin Psychopharmacol 1996;16:81-83
30. Rasmussen SA, Baer L, Eisen J, et al. Previous SRI treatment and efficacy of sertraline for OCD: combined analysis of 4 multicenter trials [poster]. Presented at the 150th annual meeting of the American Psychiatric Association; May 17-22, 1997; San Diego, Calif
31. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 1997;17:267-271
32. Koran LM, Hackett E, Rubin A, et al. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 2002;159:88-95
33. Maina G, Albert U, Bogetto F. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:33-38
34. Hollander E for the Paroxetine OCD Study Group, Allen A, Steiner M, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003;64:1113-1121
35. Ravizza I, Barzega G, Bellino S, et al. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 1996;32:167-173
36. Romano S, Goodman W, Tamura R, et al. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 2001;21:46-52
37. Ferguson D, Glass KC, Waring D, et al. Turning a blind eye: the success of blinding reported in a random sample of randomized, placebo controlled trials. BMJ 2004;328:432-434
38. Stern L, Zohar J, Hendler T, et al. The potential role of 5-HT1D receptors in the pathophysiology and treatment of obsessive-compulsive disorder. CNS Spectr 1998;3:46-49
39. Blier P, de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 1998;44:313-323
40. Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl) 1998;136:205-216
41. Bray GA, Hollander P, Klein S, et al. A 6-month randomized placebo-controlled dose ranging trial of topiramate on weight loss in obesity. Obes Res 2003;11:722-733
42. Van Ameringen M, Mancini C, Pipe B, et al. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J Clin Psychiatry 2002; 63:981-984
43. Gadde KM, Francisey DM, Wagner HR, et al. Zonisamide for weight loss in obese adults: a randomized, controlled trial. JAMA 2003;289: 1820-1825
44. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801
45. Benazzi F. Serotonin syndrome with mirtazapine-fluoxetine combination. Int J Geriatr Psychiatry 1998;13:495-496
46. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51:183-188